Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
TETREX is an oral tetracycline phosphate complex capsule approved in 1957 as a broad-spectrum antibiotic. It treats bacterial infections across multiple therapeutic areas through inhibition of bacterial protein synthesis. This legacy antibiotic remains a foundational treatment option in infectious disease management.
Product is approaching loss of exclusivity with moderate competitive pressure (30%), indicating a defensive rather than growth-oriented team focus.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on TETREX offers limited career advancement due to its mature, commoditized position and approaching LOE. Roles are primarily defensive, focused on maximizing remaining market share and ensuring regulatory/manufacturing compliance rather than strategic growth.
Worked on TETREX at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.